Computing Skin Cutaneous Melanoma Outcome from the HLA-alleles and Clinical Characteristics
Preprint
- 21 November 2019
- preprint
- Published by Cold Spring Harbor Laboratory in bioRxiv
- p. 850677
Abstract
Human Leukocyte Antigen (HLA) is an essential component of the immune system which stimulates immune cells to provide protection and defense against cancer. More than thousands of HLA alleles have been reported in the literature; but, only a specific set of HLA alleles expressed in an individual. Recognition of cancer-associated mutations by the immune system depends on the presence of a particular set of alleles, that elicit an immune response to fight against cancer. It indicates that the occurrence of specific HLA alleles also affects the outcome of the cancer patients. In the current study, prediction models have been developed using 415 skin cutaneous melanoma (SKCM) patients for predicting the overall survival of patients from their HLA-alleles. It has been observed that, the presence of certain superalleles in the patients, is responsible for improved overall survival which were referred as favourable superalleles like HLA-B*55 (HR=0.15, 95% CI 0.034 to 0.67), HLA-A*01 (HR=0.5, 95% CI 0.3 to 0.8). In contrast, presence of certain superalleles in the patients is responsible for their poor survival, those superalleles were referred as unfavourable superalleles such as HLA-B*50 (HR=2.76, 95% CI 1.284 to 5.941), HLA-DRB1*12 (HR=3.44, 95% CI 1.64 to 7.2). We developed prediction models using 14 HLA-superalleles and five clinical characteristics for predicting high-risk SKCM patients and achieve HR=4.52 (95% CI 3.088-6.609) with p-value = 8.01E-15. Lastly, we provide a web-based service to community for predicting the risk in SKCM patients (https://webs.iiitd.edu.in/raghava/skcmhrp/)Keywords
All Related Versions
- Published version: Frontiers in Genetics, 11, 221.
This publication has 46 references indexed in Scilit:
- The Pathophysiological Impact of HLA Class Ia and HLA-G Expression and Regulatory T Cells in Malignant Melanoma: A ReviewJournal of Immunology Research, 2016
- HLA and skin cancerAnais Brasileiros de Dermatologia, 2012
- “Hard” and “soft” lesions underlying the HLA class I alterations in cancer cells: Implications for immunotherapyInternational Journal of Cancer, 2010
- HLA and melanoma: multiple alterations in HLA class I and II expression in human melanoma cell lines from ESTDAB cell bankCancer Immunology, Immunotherapy, 2009
- Defective MHC class I antigen surface expression promotes cellular survival through elevated ER stress and modulation of p53 functionCell Death & Differentiation, 2008
- Human MHC architecture and evolution: implications for disease association studiesInternational Journal of Immunogenetics, 2008
- Role of Altered Expression of HLA Class I Molecules in Cancer Progression2007
- The HLA System: Genetics, Immunology, Clinical Testing, and Clinical ImplicationsYonsei Medical Journal, 2007
- The exogenous pathway for antigen presentation on major histocompatibility complex class II and CD1 moleculesNature Immunology, 2004
- The Human Major Histocompatibility Complex: Lessons from the DNA SequenceAnnual Review of Genomics and Human Genetics, 2000